Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
AAPS PharmSciTech ; 22(8): 264, 2021 Nov 03.
Artigo em Inglês | MEDLINE | ID: mdl-34734325

RESUMO

The human race is consistently striving for achieving good health and eliminate disease-causing factors. For the last few decades, scientists have been endeavoring to invent and innovate technologies that can substitute the conventional dosage forms and enable targeted and prolonged drug release at a particular site. The novel multi-matrix technology is a type of matrix formulation where the formulation is embraced to have a matrix system with multiple number of matrices. The MMX technology embraces with a combination of outer hydrophilic layer and amphiphilic/lipophilic core layer, within which drug is encapsulated followed by enteric coating for extended/targeted release at the required site. In comparison to conventional oral drug delivery systems and other drug delivery systems, multi-matrix (MMX) technology formulations afford many advantages. Additionally, it attributes for targeting strategy aimed at the colon and offers modified prolonged drug release. Thus, it has emerged rapidly as a potential alternative option in targeted oral drug delivery. However, the development of this MMX technology formulations is a exigent task and also has its own set of limitations. Due to its promising advantages and colon targeting strategy over the other colon targeted drug delivery systems, premier global companies are exploiting its potential. This article review deep insights into the formulation procedures, drug delivery mechanism, advantages, limitations, safety and efficacy studies of various marketed drug formulations of MMX technology including regulatory perspectives and future perspectives.


Assuntos
Colite Ulcerativa , Mesalamina , Anti-Inflamatórios/uso terapêutico , Budesonida/uso terapêutico , Humanos , Estudos Retrospectivos , Tecnologia
2.
J Drug Target ; 29(9): 925-940, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-33709876

RESUMO

Exosomes are membrane-based extracellular vesicles naturally released by the cells. Nano size range of exosomes and unique properties such as stability, biocompatibility and low immunogenicity are key parameters, which make them suitable as nanoparticulate drug delivery system and also considered as promising delivery carriers for future clinical use. This review outlines the composition, biogenesis, isolation and characterisation methods along with biological and clinical applications of exosomes. Further, the biopharmaceutical features of exosomes include loading method, modified exosomes and potential use of exosomes for different diseases are well explained with the current case studies. We well elaborate the future directions for clinical use of exosomes as drug delivery platforms.


Assuntos
Sistemas de Liberação de Medicamentos , Exossomos/metabolismo , Nanopartículas , Animais , Portadores de Fármacos/química , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...